Emergence of clarithromycin-resistant Helicobacter pylori (CRHP) with a high prevalence in children compared with their parents

Helicobacter

Volumn 7, Issue 5, 2002, Pages 297-305

  Taneike, Ikue ^a   Goshi, Satoshi ^a   Tamura, Yukiko ^a   Wakisaka Saito, Noriko ^a   Matsumori, Noriko ^a   Yanase, Azusa ^a   Shimizu, Toshiaki ^b   Yamashiro, Yuichiro ^b   Toyoda, Shigeru ^c   Yamamoto, Tatsuo ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c Kanagawa Prefecture Midwives and Nurses Training School Hospital   (Japan)

Author keywords

Children; Clarithromycin resistance; Helicobacter pylori; Intrafamilial transmission

Indexed keywords

AMOXICILLIN; AMPHOTERICIN B; CLARITHROMYCIN; DNA; METRONIDAZOLE; POLYMYXIN B; RIBOSOME RNA; TRIMETHOPRIM; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; DNA DETERMINATION; FEMALE; GENE MUTATION; GENE SEQUENCE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; OTITIS MEDIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION MAPPING; STOMACH BIOPSY;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 18644365083     PISSN: 10834389     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-5378.2002.00100.x     Document Type: Article

References (44)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-8.
2. Goodwin CS. Helicobacter pylori gastritis, peptic ulcer, and gastric cancer: Clinical and molecular aspects. Clin Infect Dis 1997;25:1017-9.
3. IARC Working Group. Infection with Helicobacter pylori. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 61, Schistosomes, Liver Flukes and Helicobacter Pylori. Lyon. France: International Agency for Research on Cancer, World Health Organization 1994, 177-241.
4. Sugiyama A, Maruta F, Ikeno T, et al. Helicobacter pylori infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res 1998;58:2067-9.
5. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils. Gastroenterology 1998;115:642-8.
6. Hirayama F, Takagi S, Iwao E, Yokoyama Y, Haga K, Hanada S. Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils. J Gastroeterol 1999;34:450-4.
7. Tokieda M, Honda S, Fujioka T, Nasu M. Effect of Helicobacter pylori infection on the N-methyl-N′-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in Mongolian gerbils. Carcinogenesis 1999;20:1261-6.
8. Blecker U, McKeithan TW, Hart J, Kirschner BS. Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child. Gastroenterology 1995;109:973-7.
9. Graham DY. Therapy of Helicobacter pylori: Current status and issues. Gastroenterology 2000;118:S2-S8.
10. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997;11:43-53.
11. Vakil N, Hahn B, McSorley D. Clarithromycin resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998;93:1432-5.
12. Megraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 study. Antimicrob Agents Chemother 1999;43:2747-52.
13. Kato M, Yamaoka Y, Kim JJ, et al. Regional differences in metrinidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Anitimicrob Agents Chemother 2000;44:2214-6.
14. Wang WH, Wang BCY, Mukhopadhyay AK, et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000;14:901-10.
15. Cayla R, Zerbib F, Talbi P, Megraud F, Lamouliatte H. Pre and Post-treatment clarithromycin resistance of Helicobacter pylori strains: A key factor of treatment failure. Gut 1995;37:A55.
16. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997;2:185-7.
17. Moazed D, Noller HF. Chloramphenicol, erythromycin, carbomycin and vernamycin B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA. Biochimie 1987;69:879-84.
18. Goldman RC, Zakula D, Flamm R, Beyer J, Capobinco J. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrob Agents Chemother 1994;38:1496-500.
19. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 1997;41:2621-8.
20. Wang G, Taylor DE. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamidesreptogramin B antibiotics. Antimicrob Agents Chemother 1998;42:1952-8.
21. Debets-Ossenkopp YJ, Sparrius M, Kusters JG, Kolkman JJ, Vandenbroucke-Grauls CMJE. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori FEMS Microbiol Lett 1996;142:37-42.
22. Stone GG, Shortridge D, Flamm RK, et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1996;1:227-8.
23. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clari-thromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996;40:477-80.
24. Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouliatte H, Megraud F. Macrolide resistance in Helicobacter pylori: Rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother 1997;41:2724-8.
25. Stone GG, Shortridge D, Versalovic J, et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother 1997;41:712-4.
26. Versalovic J, Osato MS, Spakovsky K, et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J Antimicrob Chemother 1997;40:283-6.
27. National Committee for Clinical Laboratory Standards. MIC interpretive standards (μg/ml) for Helicobacter pylori. In: Methods for Dilution of Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 5th Edn. Approved standard. M7-A5, Vol. 21 no. 1 (Performance Standards for Antimicrobial Susceptibility Testing; 11th Informational (Suppl.) M100-S11), Wayne, PA, USA: National Committee for Clinical Laboratory Standards 2001, 107.
28. Japan Society of Chemotherapy. Committee report. Chemotherapy (Tokyo) 1981;29:76-9.
29. Murray MG, Thompson WF. Rapid isolation of high molecular weight plant DNA. Nucl Acids Res 1980;8:4321-5.
30. Tee W. Ribosomal RNA gene restriction pattern analysis (ribotyping) of H. pylori. In: Clayton CL, Mobley HLT, eds. Helicobacter Pylori Protocols. New Jersey, USA: Humana Press, Inc. 1997, 89-98.
31. Echeverria P, Seriwatana J, Sethabutr O, Chatkaeomorakot A. Detection of diarrheogenic Escherichia coli using nucleotide probes. In: Macario AJL, de Macario EC, eds. Gene Probes for Bacteria. San Diego, CA, USA: Academic Press 1990, 95-141.
32. Tomb JF, White O, Kerlavage AR, et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997;388:539-47.
33. Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999;397:176-80.
34. Taylor DE, Jiang Q, Fedorak RN. Antibiotic susceptibilities of Helicobacter pylori strains isolated in the Province of Alberta. Can J Gastroenterol 1998;12:295-8.
35. Mendonca S, Ecclissato C, Sartori MS, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000;5:79-83.
36. Wolle K, Nilius M, Leodolter A, Muller WA, Malfertheiner P, Konig W. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis 1998;17:519-21.
37. Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000;14:893-900.
38. Lehmann FS, Drewe J, Terracciano L, Belinger C. Effect of orinidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 2000;14:305-9.
39. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in the Netherlands. J Antimicrob Chemother 1999;43:511-5.
40. Boyanova L, Spassova Z, Krastev Z, et al. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. Diagn Microbiol Infect Dis 1999;34:309-13.
41. Hua J, Ng HC, Yeoh KG, Ho KY, Ho B. Characterization of clinical isolates of Helicobacter pylori in Singapore. Microbios 1998;94:71-81.
42. Perng CL, Kim JG, El-Zimaity HM, Osato MS, Graham DY. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. Dig Dis Sci 1998;43:464-7.
43. Katelaris PH, Adamthwaite D, Midolo P, Yemomans ND, Davidson G, Lambert J. Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: The HERO study. Aliment Pharmacol Ther 2000;14:751-8.
44. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl 1996;525:73-8.